Acute heart failure (AHF) is characterized by the rapid onset or aggravation of symptoms of heart failure. The standard of care in AHF has remained largely unchanged since the 1970s, resulting in a highly genericized market. AHF patients continue to experience high rates of mortality and morbidity because no therapy to date has been able to improve hard clinical outcomes. This study evaluates how current therapies are differentiated based on their performance on key drug attributes and measures the impact of these attributes on the prescribing behavior of cardiologists. Revealing the relative importance of unmet needs helps identify the most attractive opportunities in AHF treatment.

QUESTIONS ANSWERED

  • Which drug attributes most strongly influence AHF drug selection?
  • How do cardiologists rate key current AHF therapies across select drug attributes?
  • Where are the hidden opportunities for drug development in the AHF therapy market?
  • Do U.S. and European cardiologists have different perceptions of the unmet need in the treatment of AHF?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 32 European cardiologists fielded in December 2019.

Key companies: Novartis, Johnson & Johnson, Pfizer.

Key drugs: Nitrate vasodilators, loop diuretics, inotropic sympathomimetics, PDE3 inhibitors, calcium sensitizers.

Table of contents

  • Heart Failure - Unmet Need - Detailed, Expanded Analysis Acute Heart Failure (US/EU)
    • Executive Summary
      • Unmet Need - Acute Heart Failure - Executive Summary - February 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for Acute Heart Failure and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Cardiologists' Prescribing Decisions in Acute Heart Failure
        • Importance of Efficacy Attributes to Prescribing Decisions in Acute Heart Failure: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Acute Heart Failure: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Acute Heart Failure: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Acute Heart Failure: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Acute Heart Failure: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Acute Heart Failure: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for Acute Heart Failure: United States
        • Overall Performance of Key Therapies for Acute Heart Failure: Europe
        • Mean Overall Performance of Key Therapies for Acute Heart Failure: United States and Europe
        • Relative Performance of Key Therapies for Acute Heart Failure Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Acute Heart Failure Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Acute Heart Failure Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Acute Heart Failure Across Select Safety and Tolerability Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in Acute Heart Failure
        • Surveyed Cardiologists’ Satisfaction with the Performance of Key Therapies for Acute Heart Failure on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Cardiologists’ Satisfaction with the Performance of Key Therapies for Acute Heart Failure on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Acute Heart Failure: United States
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Acute Heart Failure: Europe
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Acute Heart Failure: United States
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Acute Heart Failure: Europe
        • Key Findings: Unmet Need in Acute Heart Failure and Related Indications
        • Surveyed Cardiologists' Ascribed Level of Unmet Need in Acute Heart Failure and Related Indications: United States
        • Surveyed Cardiologists' Ascribed Level of Unmet Need in Acute Heart Failure and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the Acute Heart Failure Market and Emerging Therapy Insights
          • Opportunity: A Novel Agent That Significantly Reduces the Rate of Cardiovascular Mortality in Acute Heart Failure
          • Opportunity: A Novel Agent That Reduces the Rate of Rehospitalization for Heart Failure
          • Opportunity: A Novel Agent That Shows Significant Improvement in the Incidence of Worsening Heart Failure and Reduces the Length of Hospital Stay
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
          • Attributes of Key Current and Late-Phase Emerging Therapies for Acute Heart Failure
        • Attribute Importance and Part-Worth Utilities
          • Acute Heart Failure Target Product Profile: Attribute Importance
          • Rate of CV Mortality
          • Rate of Rehospitalization for Heart Failure
          • Effect on Length of Hospital Stay
          • Incidence of Worsening Heart Failure
          • Effect on Symptoms of Dyspnea
          • Rate of Rehospitalization for Worsening Renal Function
          • Price Per Treatment Cycle
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • Acute Heart Failure Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
          • Acute Heart Failure Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
          • Acute Heart Failure Market Simulation: Target Product Profiles Included in the Market Scenario
      • Appendix
        • Key Abbreviations
        • Bibliography

    Author(s): Dwaipayan Chatterjee, M.Pharm

    Dwaipayan Chatterjee is an Analyst in the Cardiovascular, Metabolism Renal and Hematology disease team at Decision Resources Group.

    He holds a M.Pharm degree with specialization in Pharmaceutical Chemistry from Birla Institute of Technology & Science, Pilani, Rajasthan, India. Prior joining DRG, he worked as an Equity Analyst for the U.S. Healthcare sector with Market Realist working on competitive intelligence and analysis of pharmaceutical financial data. He also worked as a market research analyst for Mordor Intelligence with experience of market sizing, forecasting, and analyzing market dynamics.


    Related Reports

    Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

    Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological...

    View Details

    Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2020

    Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophysiology...

    View Details

    Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)

    MARKET OUTLOOK First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diur...

    View Details

    Heart Failure | Disease Landscape and Forecast | G7 | 2020

    Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates...

    View Details